Dr. Clay Siegall is passionate about cancer research. The founder, president and CEO of the Washington state based Seattle Genetics, he has created a company that is a leader in the development of effective cancer treatments. Since starting the company in 1998, Dr. Siegall has overseen the development of some of the most effective targeted cancer treatments in a generation. ADCETRIS, an antibody-drug conjugate developed by Seattle Genetics, was the first ADC to receive FDA approval. It is now being used to treat cancer patients in more than 60 countries around the world.
As part of his strategic leadership, Dr. Siegall has helped Seattle Genetics to create a diverse portfolio of preclinical and clinical drugs that target several types of cancer as well as autoimmune indications. Seattle Genetics has agreed to an exclusive worldwide collaboration for the drug SGN-40 with Genentech worth over $860. The company has earned another $65 million through ADC collaborations with Bayer, Progenics, CuraGen, Genentech, Medimmune and others because of Dr. Siegall’s negotiations. A very savvy, experienced entrepreneur, Dr. Clay Siegall has done many other lucrative deals for Seattle Genetics products.
But Dr. Clay Siegall is much more than just a businessman. He has dedicated decades of his life to help ensure cancer patients get the best medical care possible. To ensure this happens, he has worked with some of the world’s top cancer research companies. He also shares his knowledge and experience by his work as a board member at Alder BioPharmaceuticals, the Fred Hutchinson Cancer Research Business Alliance, the Washington Biotechnology and Biomedical Association and a host of other organizations. He has made invaluable contributions to these organizations that have helped to advance cancer research.
At Seattle Genetics Dr. Siegall has created an atmosphere that encourages experimentation and innovation. The result has been the development of a wide array of new targeted cancer treatments. Now an industry leader, Seattle Genetics’ development pipeline is poised to unleash a number of other effective cancer treatments. Motivated by the pain he saw his father endure fighting cancer, Clay Siegall has developed better weapons to conquer the disease.